Combining A Real-World Observational Study And A Network Meta-Analysis of Randomised Controlled Trials To Determine Relative Treatment Effects In Type 2 Diabetes

Abstract

The mean basal insulin daily dose increased by 2.04 units (SD= 16.71) compared to pre switch insulin dose. The dose increase was driven by an increased dose in the first 90 days after index date. Hereafter a return to the baseline insulin dose level was observed. There was no significant weight change and of as for health expenditure there was a small increase in visits to diabetes specialist and use of self-blood glucose measurement sticks. ConClusions: In a real life setting, switch from another insulin to IDeg significantly improved glycemic control in Type 2 DM patients with no significant weight gain and only a minor initial dose increase after IDeg initiation.